Literature DB >> 24837790

Prioritizing drug targets in Clostridium botulinum with a computational systems biology approach.

Syed Aun Muhammad1, Safia Ahmed2, Amjad Ali3, Hui Huang4, Xiaogang Wu5, X Frank Yang6, Anam Naz7, Jake Chen8.   

Abstract

A computational and in silico system level framework was developed to identify and prioritize the antibacterial drug targets in Clostridium botulinum (Clb), the causative agent of flaccid paralysis in humans that can be fatal in 5 to 10% of cases. This disease is difficult to control due to the emergence of drug-resistant pathogenic strains and the only available treatment antitoxin which can target the neurotoxin at the extracellular level and cannot reverse the paralysis. This study framework is based on comprehensive systems-scale analysis of genomic sequence homology and phylogenetic relationships among Clostridium, other infectious bacteria, host and human gut flora. First, the entire 2628-annotated genes of this bacterial genome were categorized into essential, non-essential and virulence genes. The results obtained showed that 39% of essential proteins that functionally interact with virulence proteins were identified, which could be a key to new interventions that may kill the bacteria and minimize the host damage caused by the virulence factors. Second, a comprehensive comparative COGs and blast sequence analysis of these proteins and host proteins to minimize the risks of side effects was carried out. This revealed that 47% of a set of C. botulinum proteins were evolutionary related with Homo sapiens proteins to sort out the non-human homologs. Third, orthology analysis with other infectious bacteria to assess broad-spectrum effects was executed and COGs were mostly found in Clostridia, Bacilli (Firmicutes), and in alpha and beta Proteobacteria. Fourth, a comparative phylogenetic analysis was performed with human microbiota to filter out drug targets that may also affect human gut flora. This reduced the list of candidate proteins down to 131. Finally, the role of these putative drug targets in clostridial biological pathways was studied while subcellular localization of these candidate proteins in bacterial cellular system exhibited that 68% of the proteins were located in the cytoplasm, out of which 6% was virulent. Finally, this framework may serve as a general computational strategy for future drug target identification in infectious diseases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clostridium botulinum; Drug targets prioritization; In silico analysis; Interactome

Mesh:

Substances:

Year:  2014        PMID: 24837790     DOI: 10.1016/j.ygeno.2014.05.002

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  14 in total

1.  Putative vaccine candidates and drug targets identified by reverse vaccinology and subtractive genomics approaches to control Haemophilus ducreyi, the causative agent of chancroid.

Authors:  Alissa de Sarom; Arun Kumar Jaiswal; Sandeep Tiwari; Letícia de Castro Oliveira; Debmalya Barh; Vasco Azevedo; Carlo Jose Oliveira; Siomar de Castro Soares
Journal:  J R Soc Interface       Date:  2018-05       Impact factor: 4.118

2.  Novel Drug Targets for Food-Borne Pathogen Campylobacter jejuni: An Integrated Subtractive Genomics and Comparative Metabolic Pathway Study.

Authors:  Kusum Mehla; Jayashree Ramana
Journal:  OMICS       Date:  2015-06-10

3.  DRPADC: A novel drug repositioning algorithm predicting adaptive drugs for COVID-19.

Authors:  Guobo Xie; Haojie Xu; Jianming Li; Guosheng Gu; Yuping Sun; Zhiyi Lin; Yinting Zhu; Weiming Wang; Youfu Wang; Jiang Shao
Journal:  Comput Chem Eng       Date:  2022-08-04       Impact factor: 4.130

4.  Genome-wide Meta-analysis Reveals New Gene Signatures and Potential Drug Targets of Hypertension.

Authors:  Fawad Ali; Arifullah Khan; Syed Aun Muhammad; Syed Qamar Abbas; Syed Shams Ul Hassan; Simona Bungau
Journal:  ACS Omega       Date:  2022-06-20

Review 5.  In silico Methods for Identification of Potential Therapeutic Targets.

Authors:  Xuting Zhang; Fengxu Wu; Nan Yang; Xiaohui Zhan; Jianbo Liao; Shangkang Mai; Zunnan Huang
Journal:  Interdiscip Sci       Date:  2021-11-26       Impact factor: 3.492

6.  Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.

Authors:  Syed A Muhammad; Jinlei Guo; Thanh M Nguyen; Xiaogang Wu; Baogang Bai; X Frank Yang; Jake Y Chen
Journal:  Front Microbiol       Date:  2018-03-13       Impact factor: 5.640

7.  VacSol: a high throughput in silico pipeline to predict potential therapeutic targets in prokaryotic pathogens using subtractive reverse vaccinology.

Authors:  Muhammad Rizwan; Anam Naz; Jamil Ahmad; Kanwal Naz; Ayesha Obaid; Tamsila Parveen; Muhammad Ahsan; Amjad Ali
Journal:  BMC Bioinformatics       Date:  2017-02-13       Impact factor: 3.169

8.  Cellular Signaling Pathways in Insulin Resistance-Systems Biology Analyses of Microarray Dataset Reveals New Drug Target Gene Signatures of Type 2 Diabetes Mellitus.

Authors:  Syed Aun Muhammad; Waseem Raza; Thanh Nguyen; Baogang Bai; Xiaogang Wu; Jake Chen
Journal:  Front Physiol       Date:  2017-01-25       Impact factor: 4.566

9.  Genome wide meta-analysis of cDNA datasets reveals new target gene signatures of colorectal cancer based on systems biology approach.

Authors:  Umair Ilyas; Shaiq Uz Zaman; Reem Altaf; Humaira Nadeem; Syed Aun Muhammad
Journal:  J Biol Res (Thessalon)       Date:  2020-06-08       Impact factor: 1.889

10.  An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets.

Authors:  Pablo Ivan Pereira Ramos; Darío Fernández Do Porto; Esteban Lanzarotti; Ezequiel J Sosa; Germán Burguener; Agustín M Pardo; Cecilia C Klein; Marie-France Sagot; Ana Tereza R de Vasconcelos; Ana Cristina Gales; Marcelo Marti; Adrián G Turjanski; Marisa F Nicolás
Journal:  Sci Rep       Date:  2018-07-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.